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Adipose tissue secretes a variety of bioactive factors, which can regulate cardiomyocyte hypertrophy
via reactive oxygen species (ROS). In the present study we investigated whether apelin affects ROS-
dependent cardiac hypertrophy. In cardiomyocytes apelin inhibited the hypertrophic response to 5-
HT and oxidative stress induced by 5-HT- or H2O2 in a dose-dependent manner. These effects were
concomitant to the increase in mRNA expression and activity of catalase. Chronic treatment of mice
with apelin attenuated pressure-overload-induced left ventricular hypertrophy. The prevention of
hypertrophy by apelin was associated with increased myocardial catalase activity and decreased
plasma lipid hydroperoxide, as an index of oxidative stress. These results show that apelin behaves
as a catalase activator and prevents cardiac ROS-dependent hypertrophy.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cardiac hypertrophy represents a typical feature of various car-
diomyopathies including ischemic heart disease and hypertension.
Cardiomyocyte hypertrophy is induced by a variety of factors such
as mechanical load [1–3] and neurohumoral factors [4–6]. Among
humoral factors, adipocyte-derived angiotensin II and leptin have
recently attracted great attention, because of its role in the develop-
ment and progression of left ventricular hypertrophy [7–10]. We
have described a novel adipokine, produced and secreted by human
and mouse adipocytes, apelin [11]. This bioactive peptide is the
endogenous ligand of the orphan G protein-coupled receptor, APJ,
affecting many biological functions in the neuroendocrine, cardio-
vascular, and immune systems [12–14]. Apelinergic signallingchemical Societies. Published by E
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. Kunduzova).pathway is widely represented in the heart and vasculature, and
is emerging as an important regulator of cardiac function [15]. In
skeletal muscle apelin has been shown to stimulate endothelial
nitric oxide synthase [16]. In preclinical models, apelin causes nitric
oxide-dependent vasodilatation and increases cardiac contractility
in rats with normal and failing hearts [17–19]. Apelin/APJ signalling
also attenuates ischemic myocardial injury and maintains cardiac
performance in aging pressure overload [20–22]. Downregulation
of apelin and APJ expression coincides with declining cardiac per-
formance raising the possibility that diminished apelin/APJ activity
may have pathophysiologic implications [23]. Although studies in
animal models and humans suggest that cardiac failure results in
an altered balance of apelin and APJ expression, the regulatory
mechanisms for apelinergic system in failing heart are not fully
investigated.
Reactive oxygen species (ROS) have emerged as key mediators
of hypertrophic remodeling and cardiac dysfunction. In cardiomyo-
cytes, excessive ROS generation has been shown to mediate the
hypertrophic response to stretch [24] or other hypertrophic stim-
uli, such as endothelin-1 [25], angiotensin II [26], tumor necrosis
factor-a (TNF-a) [27] and leptin [28]. We have previously demon-
strated that serotonin (5-HT) induces hypertrophic growth in
cardiomyocytes via an intracellular signalling pathway involving
monoamine oxidase (MAO) A-dependent hydrogen peroxidelsevier B.V. All rights reserved.
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failing heart is subjected to increased oxidative stress, and antiox-
idant therapy has been shown to attenuate left ventricular hyper-
trophy [30,31]. These data support the hypothesis that excessive
production of ROS in concert with reduction of cardiac antioxidant
capacity play a central role in the progression of cardiac hypertro-
phy leading to heart failure.
Therefore, the purpose of the present study was to determine
in vitro and in vivo whether apelin affects cardiac H2O2-dependent
hypertrophic and oxidative stress responses. Our results show that
apelin behaves as a catalase activator and prevents cardiac ROS-
dependent hypertrophy.2. Materials and methods
2.1. Cultured neonatal rat cardiac myocyte
Primary cultures of cardiac myocytes were prepared as de-
scribed previously [26]. After treatment with collagenase type II
(Sigma), and subsequent digestion with trypsin and deoxyribonu-
clease, cells were resuspended in complete medium (Ham’s F-12
medium, 2 mmol/L L-glutamine, penicillin [100 U/mL], streptomy-
cin [100 lg/mL]) containing 10% fetal calf serum (FCS) and 10%
horse serum and then incubated for 2 h at 37 C, allowing selective
attachment of non-myocytes. Cardiomyocyte-enriched suspen-
sions were plated at a density of 3  105 cells/well onto 12-well
culture plates in complete medium. Each dish was incubated with
Ham’s F-12 medium containing 1.5% FCS for 24 h before experi-
ment. The purity of these cultures was greater than 85% as deter-
mined by staining for a-actinin.
2.2. [3H]Leucine incorporation and surface area
[3H]Leucine incorporation was measured as described previ-
ously [27]. Brieﬂy, cardiac myocytes were pretreated with ape-
lin-13 (H-4566, Bachem) at the dose of 0.1, 1, 10 and 100 nM,
the predominant apelin isoform in the human heart [32],
20 min before stimulated with 5-HT (10 lM) and coincubated
with [3H]leucine (1 lCi/ml) for 48 h. At the end of the experi-
ment, the cells were washed with phosphate buffered saline
(PBS) solution, scraped off the well, and then treated with 10% tri-
chloroacetic acid at 4 C for 60 min. The precipitates were then
dissolved in NaOH 1N and subsequently counted with a scintilla-
tion counter. For surface areas, the cells were ﬁxed with 0.5%
para-formaldehyde, permeabilized in 0.1% Triton X-100 in PBS,
and stained with a-actinin (Sigma–Aldrich) at a dilution of
1:100 by standard immunocytochemical techniques. Cell images
were viewed with a digital camera (Nikon) ﬁxed to a microscope
(Nikon). The cardiomyocyte surface area was analyzed after 48 h
treatment with apelin by the Leica Image Processing and Analysis
System. One hundred cells from randomly selected ﬁelds in three
wells were examined for each condition.
2.3. Measurement of intracellular ROS
Intracellular ROS levels were measured using the ﬂuorescence
dye H2DCF-DA (5 and 6-chloromethyl-20,70-dichlorodihydroﬂuo-
rescein diacetate-acetyl ester, abbreviated DCF throughout the text;
Invitrogen), which is a non-polar compound that is converted into a
non-ﬂuorescent polar derivative (H2DCF) by cellular esterase after
incorporation into cells as described previously [27]. On culture
day 4, cardiac myocytes were incubated with DCF-DA (5 lmol/L)
in PBS at 37 C. After incubation for 30 min, cardiomyocytes then
were pretreated with PBS or apelin for 20 min and then stimulated
with 100 lM 5-HT or 100 lM H2O2 for 60 min. Fluorescent signalswere obtained with a ﬂuorescence conversion microscope (Nikon)
and assayed by its image processing and analysis system. In each
case, three randomly selected ﬁelds in each well were selected for
examination.
2.4. Measurement of extracellular hydrogen peroxide
Extracellular H2O2 was determined using the Amplex Red
Hydrogen Peroxide Assay Kit (Invitrogen, France) according to
the manufacturer’s protocol. Fluorescence was measured in Fluoro-
Count (Packard Bioscience) using 530- and 585-nm ﬁlters for exci-
tation and emission, respectively.
2.5. Activities of antioxidant enzymes
The activities of catalase (Bachem, S-9093) and glutathione per-
oxidase (GPx) (Cayman Chemical, 703102) were measured by com-
mercially available kits. Samples were normalized by protein
concentration determined by the Bradford assay (Bio-Rad, France).
2.6. Real time RT-PCR analysis
Total RNAs were isolated from cultured neonatal rat cardiac
myocytes using the RNeasy mini kit (Qiagen). Total RNAs (300 ng)
were reverse transcribed using Superscript II reverse transcriptase
(Invitrogen) in the presence of a random hexamer. The same reac-
tion was performed without Superscript II (RT) to estimate DNA
contamination. Real time PCR was performed as previously de-
scribed [11]. The sequences of the primers for catalase were CCCA-
GAAGCCTAAGAATGCAA and TCCCTTGGCAGCTATGTGAGA and for
GPx GCTGTGCGCGCTCCAT and ACCATGTGCCCATCGATGT.
2.7. Low-density PCR array analysis
Total RNAs were isolated from heart mouse using the RNeasy
mini kit (Qiagen). TaqMan Low Density Arrays (Applied Biosys-
tems) were used in a two-step RT-PCR process. Total RNAs
(500 ng) were reverse transcribed using Superscript II reverse
transcriptase (Invitrogen) in the presence of a random hexamer.
PCR reactions were then carried out in Low Density Array using
the AB PRISM 7900HT Sequence Detection System (Applied Biosys-
tems) in 384 wells of each array preloaded with 48  8 prede-
signed TaqMan probes and primers for mouse atrial natriuretic
peptide (ANP), brain natriuretic peptide (BNP), a- and b-myosin
heavy chain (a- and b-MHC) and a-skeletal actin (a-SK-actin)
(TaqMan Gene Expression Assays, Applied Biosystems). Two nano-
grams of cDNA combined with 1 TaqMan Universal Master Mix
(AppliedBiosystems) were loaded into each well. The Low Density
Arrays were thermal cycled at 50 C for 2 min and 94.5 C for
10 min, followed by 40 cycles of 97 C for 30 s and 59.7 C for
1 min. Data were analysed using the threshold cycle (CT) relative
quantiﬁcation method.
2.8. Animal models
All experiments were performed in accordance with the rec-
ommendations of the French Accreditation of the Laboratory Ani-
mal Care and were approved by the local Centre National de la
Recherche Scientiﬁque ethics committee. In the present study
we used 7-week-old male C57BL6/J mice purchased from Charles
River Laboratories (l’Arbresle, France). Pressure overload was pro-
duced by constriction of the ascending aorta as described previ-
ously [33]. Brieﬂy, mice were anesthetized with isoﬂurane (4%),
ventilated, and the left thorax was opened at the second intercos-
tal space. Aortic constriction was performed by ligation of the
ascending aorta around a 26-gauge needle with the use of a 7-0
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Fig. 1. Pretreatment with apelin inhibits cardiac hypertrophy in vitro. (A) Apelin inhibits 5-HT-induced [3H]leucine incorporation in cultured neonatal rat cardiomyocytes.
Cardiac myocytes were pretreated with 0.1, 1, 10 and 100 nM apelin 20 min before stimulation by 5-HT (10 lM) and coincubated with [3H]leucine (1 lCi/ml) for 48 h. Results
are the mean ± S.E.M. of three independent experiments. (B) Representative ﬁelds of cardiomyocytes stained with a-actinin. Original magniﬁcation, 40. Cardiomyocytes
were stained for a-actinin and the nuclear DNA was labeled with DAPI. 5-HT-stimulated increases in cardiomyocyte size were abolished by 100 nM apelin pretreatment. (C)
Quantiﬁcation of cell cross-sectional area from experiments shown in B by measuring 100 random cells. Results are the mean ± S.E.M. of three independent
experiments.*P < 0.05 vs. control (C), **P < 0.01 vs. (C), §P < 0.05 vs. 5-HT.
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dure without ligation of the ascending aorta.
2.9. Experimental protocols
Mice were subjected to aortic constriction or the sham opera-
tion for 4 weeks. Animals were randomly divided into four groups:
(1) sham vehicle (n = 6), (2) aortic-banded vehicle (n = 7), (3) sham
apelin (n = 7), and (4) aortic-banded apelin (n = 7). Mice received
intraperitoneally apelin (0.1 lmol/kg/day) or vehicle (PBS)
15 min before aortic banding (AB) surgery and then every 24 h
for 4 weeks.
2.10. Echocardiographic studies
Animals were anesthetized with 2% isoﬂurane and examined
with non-invasive echocardiography (echocardiograph Vivid 7
ultrasound, GE) 4 weeks after AB surgery. Cardiac ventriculardimensions were measured on M-mode images at least ﬁve times
for the number of animals indicated.
2.11. Determination of lipid hydroperoxide (LPO)
Plasma LPO was measured by the Lipid Hydroperoxide Assay kit
as indicated by the manufacturer (Cayman Chemical, Ann Arbor,
MI, USA). A quantitative extraction method as provided in the kit
method for lipid hydroperoxide (LPO) assay was used to extract
LPOs into chloroform and the extract was directly used. This proce-
dure eliminates any interference caused by H2O2 or endogenous
ferric ions in the sample and provides a sensitive and reliable assay
for lipid peroxidation.
2.12. Statistical analysis
Data are expressed as mean ± S.E.M. The data was analyzed
using ANOVA followed by the Bonferroni’s test for multiple
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Fig. 2. Pretreatment with apelin inhibits ROS production in vitro. (A) Kinetics of ROS production after 5-HT stimulation in neonatal cardiomyocytes. Intracellular ROS was
detected using a ﬂuorescent probe, dihydro-20 ,70-dichloroforescin (DCF) in response to 100 lM 5-HT at 60 min. (A) Phase-contrast micrographs of cultured neonatal cardiac
myocytes and corresponding DCF ﬂuorescence within myocytes exposed to 5-HT and H2O2 in the absence or presence of apelin. Cardiomyocytes were pretreated with 1, 10
and 100 nM apelin for 20 min and then stimulated by 100 lM H2O2 or 100 lM 5-HT for 60 min. (B) Cardiomyocyte stimulation by H2O2 or 5-HT induced signiﬁcant increase
in DCF, which was abolished by apelin (A) or pargyline (P). Pargyline (an inhibitor of MAO) was used as a positive control for the inhibition of 5-HT-dependent H2O2
generation. Quantiﬁcation of DCF-DA ﬂuorescence, as per A. The ﬂuorescence intensity was expressed to the total number of cells per condition in three independent
experiments. (C), Detection of H2O2 using the Amplex Red assay. Fluorescence was measured using 530- and 585-nm ﬁlters for excitation and emission, respectively.
***P < 0.001 vs. control (C), *P < 0.05 vs. control (C), #P < 0.05 vs. 5-HT, ###P < 0.001 vs. 5-HT, §§P < 0.01 vs. H2O2.
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signiﬁcant.
3. Results
3.1. Pretreatment with apelin inhibits cardiac hypertrophy in vitro
We have previously demonstrated that 5-HT promotes cardio-
myocyte hypertrophy via an intracellular signalling pathway
involving H2O2 generation [29]. Firstly, we examined the effect of
apelin on neonatal cardiomyocyte growth induced by 5-HT. Activa-
tion of the hypertrophic responses was monitored by increased
protein synthesis and myocyte cross-sectional area. Cardiomyo-
cytes were incubated with apelin for 20 min and subsequently
treated with 10 lM 5-HT for 48 h. Incorporation of [3H]-leucin into
neonatal rat cardiomyocytes was signiﬁcantly increased by 5-HT
stimulation (Fig. 1A). The hypertrophic response to 5-HT was abol-
ished by apelin in a dose-dependent manner (Fig. 1A). Additionally,
the increase in cardiomyocyte size seen after 48 h of culture in the
presence of 5-HT was also markedly reduced by apelin (Fig. 1B and
C).3.2. Pretreatment with apelin inhibits H2O2 production
In cardiomyocytes, the development of hypertrophy is coupled
with ROS generation, which trigger the hypertrophic signaling
pathways [32]. We have previously demonstrated that stimula-
tion of cardiomyocytes with 100 lM 5-HT induces MAO-depen-
dent H2O2 generation [34]. To determine H2O2 production, a
ﬂuorescent probe, DCF-DA was used in isolated cardiomyocytes.
As demonstrated in Fig. 1A and B, exposure of cardiomyocytes
to 100 lM 5-HT caused a signiﬁcant increase in H2O2 production
compared to control which was completely blocked by apelin at
the doses of 1, 10 and 100 nM or pargyline 5 lM (an inhibitor of
MAOs). In these experiments, pargyline was used as a positive
control for the inhibition of 5-HT-dependent H2O2 generation
by MAO. Quantiﬁcation of the DCF-DA ﬂuorescence revealed that
pretreatment of cardiomyocytes with 1, 10, 100 nM of apelin sig-
niﬁcantly inhibited 5-HT-induced H2O2 generation. Apelin alone
(1, 10, 100 nM) exerted no effect on DCF-DA ﬂuorescence inten-
sity. To conﬁrm our ﬁndings, similar experiments were per-
formed inducing oxidative damage by addition of exogenous
H2O2. Similar to 5-HT, the treatment with apelin signiﬁcantly
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Fig. 3. Apelin stimulates catalase activity in vitro. (A) Apelin increased activity of catalase in cultured neonatal rat cardiomyocytes. Cardiomyocytes were treated with apelin
(1, 10 and 100 nM) for 80 min. Catalase activity was expressed as percentage of control in 4 independent experiments. (B) Apelin upregulates cardiomyocyte catalase mRNA
expression in cardiomyocytes. (C) Apelin stimulation of cardiomyocytes did not affect glutathione peroxidase (GPx) acticity. Activity of GPx was determined from the rate of
oxidation of NADPH and was measured spectrophotometrically at 340 nm. (D) Apelin did not affect GPx mRNA expression in cardiomyocytes. The expression of catalase and
GPx mRNAs in cardiomyocytes were measured by RT-PCR. The results were reproducible in three separate experiments. *P < 0.05 vs. control (C).
C. Foussal et al. / FEBS Letters 584 (2010) 2363–2370 2367decreased H2O2-induced cardiomyocyte DCF-DA ﬂuorescence
intensity (Fig. 2B). In addition, inhibition of 5-HT-dependent
H2O2 generation by apelin was conﬁrmed using the Amplex
Red assay (Fig. 2C).
In order to determine whether the antioxidant properties of
apelin involved the regulation of H2O2-degrading enzymes, we
tested the effect of apelin on activity and expression of catalase
and GPx. As shown in Fig. 3A and B, treatment of cells with 1, 10,
or 100 nM apelin increased catalase mRNA and activity as com-
pared to control. In contrast, GPx mRNA expression and activity
were not affected by apelin in cardiomyocytes (Fig. 3C and D).
3.3. Chronic treatment with apelin inhibits cardiac hypertrophy in vivo
To further determine whether apelin is involved in hypertro-
phic remodeling, we evaluated the effects of chronic treatment
with apelin on pressure-overload-induced cardiac hypertrophy in
mice. As shown in Fig. 4A, heart weight to body weight (HW/
BW) ratio signiﬁcantly increased by 25% in vehicle-treated AB
mice. In contrast, cardiac hypertrophic growth was blunted signif-
icantly in apelin-treated AB mice. Furthermore, microscopic analy-
sis of histological sections revealed that the increase in the
cardiomyocyte cross-sectional area was reduced signiﬁcantly in
apelin-treated mice as compared with vehicle-treated AB mice
(Fig. 4B). These ﬁndings were completed by echocardiographic
analysis demonstrating a signiﬁcant decreases in interventricular
septal wall thickness (IVST) and left ventricular posterior wall
thickness (LVPWT) in apelin-treated AB mice as compared with
vehicle-treated AB mice (Fig. 4C).
We next investigated the effects of chronic treatment with
apelin on the hypertrophic gene expression in response to pressure
overload in mice. Treatment of AB mice with vehicle induced
the expression of foetal genes such as ANP, BNP, b-MHC and
a-SK-actin, associated with the decrease in the expression of adult
gene a-MHC. In contrast, treatment of AB mice with apelin signif-
icantly attenuated expression of hypertrophic genes (Fig. 4D).3.4. Chronic treatment with apelin reduces oxidative stress in
hypertrophied hearts
Oxidative stress is known to play an important role in the devel-
opment and progression of left ventricular hypertrophy and heart
failure [25–30]. Therefore, we assessed whether a marker of oxida-
tive stress, LPO, and antioxidant catalase activity were affected by
chronic apelin treatment in mice subjected to pressure overload for
4 weeks. As shown in Fig. 5A, chronic treatment with apelin in AB
mice led to a signiﬁcant decrease in plasma LPO as compared to the
vehicle-treated AB mice. There was no signiﬁcant difference in
myocardial catalase activity between the vehicle-treated AB group
and sham groups. Chronic treatment with apelin signiﬁcantly in-
creased myocardial catalase activity in AB mice as compared to
vehicle-treated AB mice (Fig. 5B).
4. Discussion
Adipose tissue secrets a variety of bioactive factors which can
directly or indirectly modulate cardiomyocyte hypertrophy via
ROS generation: angiotensin II, TNF-a, leptin [26–28]. In the pres-
ent study, we provide the ﬁrst evidence for the role of apelin in the
activation of myocardial catalase during cardiac hypertrophic
remodeling. Indeed, in neonatal cardiomyocytes, apelin signiﬁ-
cantly inhibited 5-HT-induced hypertrophy and H2O2 generation
and stimulated catalase activity. In addition, we have demon-
strated that apelin signiﬁcantly prevents the progression of cardiac
hypertrophic remodeling induced by pressure overload. Apelin
preserved cardiac function by inhibiting oxidative stress and stim-
ulating catalase activity supporting the premise that apelin is a po-
tent regulator of cardiomyocyte antioxidant reserve against
oxidative stress during hypertrophic remodeling of the heart.
Increased oxidative stress resulting from enhanced production
of ROS and/or inadequate mechanisms of antioxidant defenses
has been recognized as a critical mechanism in the initiation of car-
diac dysfunction and transition from hypertrophy to heart failure
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2368 C. Foussal et al. / FEBS Letters 584 (2010) 2363–2370[35]. Numerous studies have demonstrated that failing heart is
subjected to increased oxidative stress, and antioxidant strategies
have been proposed to prevent the progression and development
of chronic heart failure [30,31]. In the present study, we show that
apelin acts as a key regulator of cardiomyocyte defenses against
oxidative stress. Indeed, we found that apelin markedly reduces
5-HT- or H2O2-induced oxidative stress in neonatal cardiomyo-
cytes. The fact that apelin also signiﬁcantly stimulated mRNA
expression and activity of catalase, a major antioxidant enzyme
responsible for conversion of H2O2 to H2O and O2 [31], suggests
that apelin plays an important role in the regulation of antioxidant
catalase status of the cardiomyocytes under stress conditions. In
fact, recent studies have reported that apelin exhibits direct cardio-
protective activity against ischemia/reperfusion injury, however,
the mechanism of apelin action is not completely clear. Our dem-
onstration that apelin inhibits H2O2 generation and upregulates
antioxidant catalase activity in cardiomyocytes may be one of
the key mechanisms for the protective effect of this adipokine
against myocardial damage. Importantly, in support of our data
in cultured cardiomyocytes, we demonstrated that in vivo chronic
treatment of AB mice with apelin stimulates myocardial catalase
activity and prevents pressure overload-induced increase in plas-
ma LPO level, an index of oxidative stress. In physiological condi-
tion catalase participates to the basal control of intracellular
redox state. Upon hypertrophic stimuli, cardiac ROS signiﬁcantly
increase and participate to progression of left ventricular hypertro-
phy. In this case, it is concevaible that expression/activity ofcatalase may be regulated by factors and mechanisms inactive in
basic situations. This may explain the fact that regulation of cata-
lase activity by apelin is evident only during hypertrophic stimuli
and suggests that apelin may play an important role in the activa-
tion of antioxidant system in hypertrophied hearts. In support of
our ﬁndings, a recent study showed that apelin enhanced superox-
ide dismutase activity in cardiomyocytes [36]. Further studies will
be necessary to dissect the molecular mechanisms involved in
antioxidant activity of apelin.
Cardiac hypertrophy is regarded as a functional consequence of
many heart diseases [37], including hypertension, aortic and mitral
valve disease, and heart failure. Although initially compensatory,
progressive and especially uncontrolled hypertrophy can lead to
contractile dysfunction and subsequent heart failure [38]. Circum-
stantial evidence suggests that an inadequate antioxidant defense
capacity plays a crucial role in cardiac hypertrophy. In cardiomyo-
cytes, catalase is a target of a variety of hypertrophic stimuli such
as TNF-a, phenylephrine and angiotensin II. These stimuli induce a
decrease in catalase levels and an increase in ROS formation [39].
In addition, it has been shown that leptin-induced ROS generation
and hypertrophy can be blocked by catalase [28], suggesting that
catalase participate in the regulation of cardiac hypertrophy. Our
present study has clearly demonstrated that apelin acts as a regu-
lator of cardiomyocyte hypertrophic growth. In support of in vitro
study, we demonstrates that in vivo chronic treatment of mice
with apelin attenuated left ventricular hypertrophy induced by
pressure overload, as assessed by HW/BW ratio, echocardiographic
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Fig. 5. Chronic treatment with apelin prevents oxidative stress in hypertrophied
hearts. (A) Effect of treatment with apelin on oxidative stress in mice. Oxidative
stress was evaluated by plasma lipid hydroperoxide (LPO) level in mice subjected to
banding aortic (AB) or the sham operation (Sham) at 4 weeks. Mice were treated
with vehicle (PBS) or apelin (0.1 lmol/kg/day, i.p.) for 4 weeks. (B) Effect of
treatment with apelin on myocardial catalase activity. The activity of catalase was
measured in hearts from vehicle- or apelin-treated AB and Sham mice by
ﬂuorescent catalase detection kit. *P < 0.05 vs. vehicle-Sham, **P < 0.01 vs. vehicle-
AB, #P < 0.05 vs. vehicle-AB.
C. Foussal et al. / FEBS Letters 584 (2010) 2363–2370 2369analysis, cardiac myocyte cross-sectional area measurements and
hypertrophic gene expressions. Interestingly, recent study in ape-
lin knockout mice have delineated important role of apelin in
aging-associated cardiac contractility and pressure overload [22].
However, in relation to pressure overload-induced heart failure,
the authors observed a marked tendency to develop hypertrophy
in apelin knockout mice than wild-type mice. Indeed, at 1, 2 and
12 weeks after AB, HW/BW ratio was always slightly higher in
AB apelin knockout than wild-type mice, but this difference did
not reach statistic difference at any time points of analysis. Further
studies are warranted to delineate more precisely the role of ape-
linergic system in the transition from a maladaptive cardiac hyper-
trophy to chronic heart failure.
Taken together, the present study delivers important new in-
sights to the mechanisms of apelin action in cardiomyocytes link-
ing H2O2 and inadequate antioxidant catalase defense to cardiac
remodeling. Our results revealed that apelin plays a central role
in the activation of cardiac catalase activity in hypertrophied
hearts. Identiﬁcation of apelin as a potent catalase activator in
cardiomyocytes may provide a new therapeutic strategy to stimu-
late antioxidant capacity of failing heart.
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